On April 16, 2014, targeted therapy for systemic lupus erythematosus: international working group recommendations were published online in Ann Rheum Dis. Participants in the development of this recommendation included physicians in rheumatology, nephrology, dermatology, internal medicine, clinical immunology, and one patient representative. Possible therapeutic targets were evaluated and targeted therapy guidelines were introduced. The key points of treat-to-target therapy for SLE are: 1. The goal of treatment for SLE should be remission of systemic symptoms and organ manifestations, or the maintenance of minimal disease activity despite failure to achieve remission; remission or disease activity is determined by a confirmed index of lupus activity and/or organ-specific markers. 2. Prevention of SLE flares (especially severe flares) is a realistic goal and should be a therapeutic goal. 3. For clinically asymptomatic patients, escalation of therapy based solely on stable or sustained serologic activity is not recommended. 4. Given that damage (from lupus itself, treatment, or concomitant disease) predicts subsequent imminent injury and death, prevention of damage should be the primary therapeutic goal for SLE. 5. In addition to controlling disease activity and preventing damage, factors that have a negative impact on health-related quality of life (HRQOL), such as fatigue, pain and depression, should also be addressed. 6. Early detection and treatment of kidney injury in patients with lupus is highly recommended. 7. Immunosuppressive maintenance therapy is recommended for at least 3 years after induction therapy for lupus nephritis in order to achieve the desired regression. 8. For maintenance treatment of lupus, the lowest hormone dose that can control the disease should be used, and hormones should be completely withdrawn as much as possible. 9. Prevention and treatment of diseases associated with antiphospholipid syndrome (APS) should be the goal of treatment for SLE, and treatment recommendations are the same as for primary APS. 10.Regardless of other therapeutic drugs, antimalarial drugs should be used with caution. 11. Adjuvant therapies such as antihypertensive, lipid-lowering and glucose-lowering should be considered to control the comorbidities in patients with lupus.